The opportunity to present original research, case series, case reports, and review articles to the San Diego Dermatology Symposium attendees is an integral part of the conference’s continuing education program. Encore abstracts/posters are permitted. We will allow posters with data that has already been published within the last 6 months, assuming that appropriate copyright permissions are obtained from the journal. Posters will be on display at the meeting on poster boards and will be available on the SDDS website until August 31, 2025.
There are three poster categories: Posters
Top Poster Competition
Fee: $125 per poster
Eligible to enter: Medical students, residents, fellows and dermatologists who graduated in 2022-2024
All posters are to be submitted electronically via the San Diego Dermatology Symposium website by Sunday, January 19, 2025. Digital posters must be formatted to 1920 W x 1080 H in size, landscape orientation and in PDF format.
All submissions will be reviewed and accepted based on scientific value and educational need. Accepted poster submissions will be posted on the SDDS website until December 31, 2025.
Top poster recipients will be notified and invited to present at the 2025 San Diego Dermatology Symposium no later than Friday, January 25, 2025.
The top posters will be selected for a short oral presentation during a 60-minute poster session on the afternoon of Friday, February 7, 2025. *Please do not bring a physical poster to the conference. You will present at the podium with a power point presentation only.*
If you are selected and invited to attend the SDDS program as a top poster, at least one author of the poster must register for the conference as well as attend in-person. Travel expenses are the responsibility of the author.
e-Poster
e-Posters are posted online on the website only.
Fee: $75 per poster
Eligible: Medical Students only
Please allow up to 1 week from date of submission for notification of approval or denial.
E-posters are not eligible for a top poster presentation, and medical students who submit an e-poster are not eligible to register for the symposium.
All submissions will be reviewed and accepted based on scientific value and educational need. Accepted poster submissions will be posted on the SDDS website December 31, 2025.
Industry Poster
Fee: $775
Not eligible for top poster presentation at conference.
Submission of an industry poster constitutes a commitment for at least one author to register and attend the conference. For the industry poster break on Saturday morning, at least one author for each industry poster must be present and stand next to the poster during this break.
Industry Poster Printing Guidelines: Authors are responsible for printing their poster boards on a foam core sign. Posters must be printed on foam core, 48 W x 36 H in size (landscape).
Poster by attending physician/NP/PA
Fee: $500
Not eligible for top poster presentation at conference.
Poster Submission Rules & Guidelines
All posters are due by 11:59pm Pacific Time on January 19, 2025. After this date/time, the submissions site will close automatically and can no longer accept submissions. There will be no exceptions to this policy.
There is no limit on the number of posters a company/person may submit.
Payment is required upon submission of the form.
Posters fees are non-refundable.
Pricing is available if interested in additional features such as uploading to the SDDS website audio slides, audio files/commentaries, and author videos.
Content: Inclusion of graphs, tables and other visuals is strongly recommended to enhance engagement. Include all authors and affiliations. All authors must disclose financial relationships. One original author of a poster is required to register for the symposium. If you have multiple posters, each poster must have a unique author registered for the symposium.
Commercialism: Any display at the San Diego Dermatology Symposium in which cost is underwritten by a pharmaceutical company or other entity must avoid commercialism. Drugs, instrumentation, or devices must not use brand names. If such situations occur, the author/exhibitor is responsible for identifying and clearly stating on the poster that a portion or portions of the cost were provided by the commercial company named.
Brand Names: Generic or scientific names of drugs/devices should be used in place of brand names. If brand name is necessary to understand poster content, it should be used only once (after the first mention of the drug or device’s name). Pharmaceutical or other support of any study should be acknowledged at the end of the poster.
Copyright: Copyright is shared. The Dermatology Research and Education Foundation owns copyright for its own use. Author(s) retain the rights for all other uses.
Note to poster submitters: if a poster is accepted (including oral presentations), travel is your own responsibility and not reimbursed by the symposium.
There are three poster categories: Posters
Top Poster Competition
Fee: $125 per poster
Eligible to enter: Medical students, residents, fellows and dermatologists who graduated in 2022-2024
All posters are to be submitted electronically via the San Diego Dermatology Symposium website by Sunday, January 19, 2025. Digital posters must be formatted to 1920 W x 1080 H in size, landscape orientation and in PDF format.
All submissions will be reviewed and accepted based on scientific value and educational need. Accepted poster submissions will be posted on the SDDS website until December 31, 2025.
Top poster recipients will be notified and invited to present at the 2025 San Diego Dermatology Symposium no later than Friday, January 25, 2025.
The top posters will be selected for a short oral presentation during a 60-minute poster session on the afternoon of Friday, February 7, 2025. *Please do not bring a physical poster to the conference. You will present at the podium with a power point presentation only.*
If you are selected and invited to attend the SDDS program as a top poster, at least one author of the poster must register for the conference as well as attend in-person. Travel expenses are the responsibility of the author.
e-Poster
e-Posters are posted online on the website only.
Fee: $75 per poster
Eligible: Medical Students only
Please allow up to 1 week from date of submission for notification of approval or denial.
E-posters are not eligible for a top poster presentation, and medical students who submit an e-poster are not eligible to register for the symposium.
All submissions will be reviewed and accepted based on scientific value and educational need. Accepted poster submissions will be posted on the SDDS website December 31, 2025.
Industry Poster
Fee: $775
Not eligible for top poster presentation at conference.
Submission of an industry poster constitutes a commitment for at least one author to register and attend the conference. For the industry poster break on Saturday morning, at least one author for each industry poster must be present and stand next to the poster during this break.
Industry Poster Printing Guidelines: Authors are responsible for printing their poster boards on a foam core sign. Posters must be printed on foam core, 48 W x 36 H in size (landscape).
Poster by attending physician/NP/PA
Fee: $500
Not eligible for top poster presentation at conference.
Poster Submission Rules & Guidelines
All posters are due by 11:59pm Pacific Time on January 19, 2025. After this date/time, the submissions site will close automatically and can no longer accept submissions. There will be no exceptions to this policy.
There is no limit on the number of posters a company/person may submit.
Payment is required upon submission of the form.
Posters fees are non-refundable.
Pricing is available if interested in additional features such as uploading to the SDDS website audio slides, audio files/commentaries, and author videos.
Content: Inclusion of graphs, tables and other visuals is strongly recommended to enhance engagement. Include all authors and affiliations. All authors must disclose financial relationships. One original author of a poster is required to register for the symposium. If you have multiple posters, each poster must have a unique author registered for the symposium.
Commercialism: Any display at the San Diego Dermatology Symposium in which cost is underwritten by a pharmaceutical company or other entity must avoid commercialism. Drugs, instrumentation, or devices must not use brand names. If such situations occur, the author/exhibitor is responsible for identifying and clearly stating on the poster that a portion or portions of the cost were provided by the commercial company named.
Brand Names: Generic or scientific names of drugs/devices should be used in place of brand names. If brand name is necessary to understand poster content, it should be used only once (after the first mention of the drug or device’s name). Pharmaceutical or other support of any study should be acknowledged at the end of the poster.
Copyright: Copyright is shared. The Dermatology Research and Education Foundation owns copyright for its own use. Author(s) retain the rights for all other uses.
Note to poster submitters: if a poster is accepted (including oral presentations), travel is your own responsibility and not reimbursed by the symposium.
Posters
TOP 3 POSTER
Successful Treatment of Cosmetic and Functional Deficits Secondary to Metastatic Squamous Cell Carcinoma with Poly-L-Lactic-Acid Dermal Filler
Catherine A. Brahe, MD, Willis H. Lyford, MD
Successful Treatment of Cosmetic and Functional Deficits Secondary to Metastatic Squamous Cell Carcinoma with Poly-L-Lactic-Acid Dermal Filler
Catherine A. Brahe, MD, Willis H. Lyford, MD
TOP 3 POSTER
Selecting an Iontophoresis Device: A Source of Consternation
Peichi Chou, BA, Amylee Martin, MD, Marina K Ibraheim, MD, Harry Dao, Jr., MD, FAAD
Selecting an Iontophoresis Device: A Source of Consternation
Peichi Chou, BA, Amylee Martin, MD, Marina K Ibraheim, MD, Harry Dao, Jr., MD, FAAD
TOP 3 POSTER
Utilization trends for Mohs micrographic surgery versus wide local excision for melanoma: a 5-year, global analysis
Karishma S. Shah, BS, Ajay N. Sharma, MD, MBA, Nima Gharavi, MD, PhD, Margit L. Juhasz, MD
Utilization trends for Mohs micrographic surgery versus wide local excision for melanoma: a 5-year, global analysis
Karishma S. Shah, BS, Ajay N. Sharma, MD, MBA, Nima Gharavi, MD, PhD, Margit L. Juhasz, MD
CD20 Negative Primary Cutaneous Diffuse Large B Cell Lymphoma, Leg Type with rapidly progressing skin lesions.
Carol Andreina Avila Hernandez, MD, Hector Arreaza, MD, Michelle Rivera, MD2
Carol Andreina Avila Hernandez, MD, Hector Arreaza, MD, Michelle Rivera, MD2
Beyond Ultraviolet (UV) Radiation: Occupational Hazards and Their Potential Synergistic Skin Effects on Flight Crew
Jennifer Ranes, MD, Andrej Slominski, MD, Tess Tarasen, BS, Lesley Flynt, MD, Rami Al Rohil, MD, Kristine Ferrone, PhD, Ashley Tarasen, MD
Jennifer Ranes, MD, Andrej Slominski, MD, Tess Tarasen, BS, Lesley Flynt, MD, Rami Al Rohil, MD, Kristine Ferrone, PhD, Ashley Tarasen, MD
VISIBLE Cohort B: Guselkumab Demonstrates Significant Scalp Clearance at Week 16 in Participants With Moderate-to-Severe Scalp Psoriasis Across All Skin Tones
Alexis, MD, McMichael, MD, Bhutani, MD, Rodriguez, MD, Grimes, MD, Kindred, MD, Yadav, MD, Yeung, MD, Choi, MD, Alkousakis, MD, Chan, MD, Rowland, ARNP, Jeyarajah, PhD, Gao, PhD, Salgado, PhD, Park-Wyllie, PharmD, S.R. Desai, MD
Alexis, MD, McMichael, MD, Bhutani, MD, Rodriguez, MD, Grimes, MD, Kindred, MD, Yadav, MD, Yeung, MD, Choi, MD, Alkousakis, MD, Chan, MD, Rowland, ARNP, Jeyarajah, PhD, Gao, PhD, Salgado, PhD, Park-Wyllie, PharmD, S.R. Desai, MD
Deucravacitinib in plaque psoriasis: 3-year safety and efficacy results from the phase 3 POETYK PSO-1 and PSO-2 trials
April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt
April W. Armstrong, Mark Lebwohl, Richard B. Warren, Howard Sofen, Shinichi Imafuku, Mamitaro Ohtsuki, Lynda Spelman, Thierry Passeron, Kim A. Papp, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Bruce Strober, Diamant Thaçi, Andrew Blauvelt
Real-world effectiveness and safety in a Phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Neal Bhatia, MD, J Gabriel Vasquez, MD, Jacob Mathew, PharmD, Ranga Gogineni, PhD, Jayme Heim, MSN, FNP-BC
Neal Bhatia, MD, J Gabriel Vasquez, MD, Jacob Mathew, PharmD, Ranga Gogineni, PhD, Jayme Heim, MSN, FNP-BC
Dupilumab Is Efficacious in Patients With Prurigo Nodularis Regardless of Atopic Comorbidities: Pooled Results From Two Phase 3 Trials (LIBERTY-PN PRIME and PRIME2)
Brian S. Kim, MD; Krystal Ngo, Pharm D; Margarida Gonçalo, MD, PhD; Tsukasa Ugajin, MD, PhD; Amy Praestgaard, MSc; Melanie Makhija, MD; Joseph Zahn, MD; Ashish Bansal, MD, MBA; Simmi Wiggins, PhD
Brian S. Kim, MD; Krystal Ngo, Pharm D; Margarida Gonçalo, MD, PhD; Tsukasa Ugajin, MD, PhD; Amy Praestgaard, MSc; Melanie Makhija, MD; Joseph Zahn, MD; Ashish Bansal, MD, MBA; Simmi Wiggins, PhD
Dupilumab is Efficacious in Patients with Prurigo Nodularis Regardless of Stable Use of Topical Corticosteroids and Topical Calcineurin Inhibitors: Pooled Results from Two Phase 3 Trials (LIBERTY-PN PRIME and PRIME2)
Brian S. Kim, MD; Jean Pham, Pharm D; Gil Yosipovitch, MD; Shawn G. Kwatra, MD; Sonja Ständer, MD; Nicholas Mollanazar, MD, MBA; Genming Shi, PhD; Ashish Bansal, MD, MBA; Melanie Makhija, MD
Brian S. Kim, MD; Jean Pham, Pharm D; Gil Yosipovitch, MD; Shawn G. Kwatra, MD; Sonja Ständer, MD; Nicholas Mollanazar, MD, MBA; Genming Shi, PhD; Ashish Bansal, MD, MBA; Melanie Makhija, MD
Safety assessments in the multinational Phase 3 THRIVE-AA1 trial with CTP-543 (deuruxolitinib) in adult patients with alopecia areata
Brett King, MD, PhD; Natasha A. Mesinkovska, MD, PhD; Maryanne Makredes Senna, MD; Arash Mostaghimi, MD; Colleen Hamilton, MS; James Cassella, PhD
Brett King, MD, PhD; Natasha A. Mesinkovska, MD, PhD; Maryanne Makredes Senna, MD; Arash Mostaghimi, MD; Colleen Hamilton, MS; James Cassella, PhD
Efficacy of the oral JAK1/JAK2 inhibitor CTP-543 (deuruxolitinib) in adult patients with alopecia areata: results from the multinational double-blind, placebo-controlled THRIVE-AA1 Phase 3 trial
Maryanne Makredes Senna, MD, Brett King, MD, PhD, Natasha A. Mesinkovska, MD, PhD, Arash Mostaghimi, MD, Colleen Hamilton, MS, James Cassella, PhD
Maryanne Makredes Senna, MD, Brett King, MD, PhD, Natasha A. Mesinkovska, MD, PhD, Arash Mostaghimi, MD, Colleen Hamilton, MS, James Cassella, PhD
Dupilumab Improves Itch in Chronic Spontaneous Urticaria: LIBERTY-CSU CUPID Study A
Marcus Maurer, MD; Arpan Patel, Pharm D; Thomas B. Casale, MD; Sarbjit S. Saini, MD; Moshe Ben-Shoshan, MD; Philip Sugerman, MDSc, PhD; Allen Radin, MD; Jennifer Maloney, MD; Raolat Abdulai, MD, MMSc; Eric Mortensen, MD, PhD; Deborah Bauer, MSc; Elizabeth Laws, PhD
Marcus Maurer, MD; Arpan Patel, Pharm D; Thomas B. Casale, MD; Sarbjit S. Saini, MD; Moshe Ben-Shoshan, MD; Philip Sugerman, MDSc, PhD; Allen Radin, MD; Jennifer Maloney, MD; Raolat Abdulai, MD, MMSc; Eric Mortensen, MD, PhD; Deborah Bauer, MSc; Elizabeth Laws, PhD
Deucravacitinib, an oral, allosteric, selective tyrosine kinase 2 inhibitor, in patients with plaque psoriasis screening positive for psoriatic arthritis in POETYK PSO-1 and PSO-2: Effect on joint pain and peripheral joint disease vs placebo and apremilast
Joseph F. Merola, Philip J. Mease, April W. Armstrong, Vibeke Strand, Thomas Lehman, Jiyoon C. Choi, Brandon Becker, Yichen Zhong, Matthew J. Colombo, Diamant Thaçi, Androniki Bili, Alice B. Gottlieb
Joseph F. Merola, Philip J. Mease, April W. Armstrong, Vibeke Strand, Thomas Lehman, Jiyoon C. Choi, Brandon Becker, Yichen Zhong, Matthew J. Colombo, Diamant Thaçi, Androniki Bili, Alice B. Gottlieb
Evaluation of eyebrow and eyelash regrowth and patient satisfaction in the Phase 3 THRIVE-AA1 trial with CTP-543 (deuruxolitinib) in adult patients with alopecia areata
Arash Mostaghimi, MD; Natasha A. Mesinkovska, MD, PhD; Maryanne Makredes Senna, MD; Brett King, MD, PhD; Colleen Hamilton, MS; James Cassella, PhD
Arash Mostaghimi, MD; Natasha A. Mesinkovska, MD, PhD; Maryanne Makredes Senna, MD; Brett King, MD, PhD; Colleen Hamilton, MS; James Cassella, PhD
Real-world evidence confirms risk stratification of the 31-GEP and i31-GEP in prospectively tested patients with stage I-III cutaneous melanoma
David Pariser, MD, Jeffrey Sussman, MD, Brian Martin, PhD, Rhiannon Johnson, Lindsay Ackerman, MD, Craig A. Kraffert, MD, Abel Jarell, MD
David Pariser, MD, Jeffrey Sussman, MD, Brian Martin, PhD, Rhiannon Johnson, Lindsay Ackerman, MD, Craig A. Kraffert, MD, Abel Jarell, MD
Facial exogenous ochronosis treated with the Picosecond laser
Dr. Lenore Sikorski (MD), Anjalee Chopra (B.S)
Dr. Lenore Sikorski (MD), Anjalee Chopra (B.S)
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a Phase 3b, randomized, double-blind, placebo-controlled trial
Howard L Sofen, MD, Kurt Gebauer, MBBS, Lynda Spelman, MBBS, Paul S Yamauchi, MD, Siu-Long Yao, PhD, Mudgal Kothekar, MD, Tushar Nishandar, MD, Iris Kopeloff, MD, Michael Crane, PhD, Ranga Gogineni, PhD, Jerry Bagel, MD
Howard L Sofen, MD, Kurt Gebauer, MBBS, Lynda Spelman, MBBS, Paul S Yamauchi, MD, Siu-Long Yao, PhD, Mudgal Kothekar, MD, Tushar Nishandar, MD, Iris Kopeloff, MD, Michael Crane, PhD, Ranga Gogineni, PhD, Jerry Bagel, MD
Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Bruce Strober, Howard Sofen, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew F. Alexis, Diamant Thaçi, Andrew Blauvelt, Mark Lebwohl
Bruce Strober, Howard Sofen, Shinichi Imafuku, Carle Paul, Melinda Gooderham, Lynda Spelman, Seong Jun Seo, Thierry Passeron, Renata M. Kisa, Victoria Berger, Eleni Vritzali, Kim Hoyt, Matthew J. Colombo, Subhashis Banerjee, Matthias Augustin, Linda Stein Gold, Andrew F. Alexis, Diamant Thaçi, Andrew Blauvelt, Mark Lebwohl
Advances in Non-Invasive Imaging for Dermatofibrosarcoma Protuberans
Yanci A. Algarin, BS, Anika Pulumati, BS, Jiali Tan, BS, Nathalie Zeitouni, MD
Yanci A. Algarin, BS, Anika Pulumati, BS, Jiali Tan, BS, Nathalie Zeitouni, MD
Effectiveness of Ileal Bile Acid Transporter Inhibitors (IBAT) in Treating Pruritus in Progressive Familial Intrahepatic Cholestasis: A Meta-Analysis
Luis F. Andrade, BS, Kayla D. Mashoudy, BS, Parsa Abdi, BASc, Peyton Warp, BS, Linh Ton, BA, Gil Yosipovitch, MD
Luis F. Andrade, BS, Kayla D. Mashoudy, BS, Parsa Abdi, BASc, Peyton Warp, BS, Linh Ton, BA, Gil Yosipovitch, MD
Acquired Vulvar Lymphatic Anomaly: A Systematic Review
Alex Balfour, BS, Amber Duong, BS, Christina Kraus, MD
Alex Balfour, BS, Amber Duong, BS, Christina Kraus, MD
When will the TH1 switch make you switch? A case report of a dupilumab-induced psoriasiform rash over 6 years
Sarah G Brooks, BA, Gil Yosipovitch, MD
Sarah G Brooks, BA, Gil Yosipovitch, MD
Artificial intelligence chatbots in dermatology: a national online cross-sectional survey of dermatologists
Julian Cortes, BS, Taraneh Paravar, MD, Reid Oldenburg, MD, PhD
Julian Cortes, BS, Taraneh Paravar, MD, Reid Oldenburg, MD, PhD
Systemic Medication and Hospitalization Trends by Race in Patients with Psoriasis in the United States
Rini Desai, BS, Chase Irwin, MS, Mitchell Davis, MD, Mariana McCune, BS
Rini Desai, BS, Chase Irwin, MS, Mitchell Davis, MD, Mariana McCune, BS
Allergic Reactions to Red Tattoo Ink: Comparison of Two Patients with Secondary Dermatologic Consequences
Kim Ross, MD, Danielle Garcia, BS, Larissa De La Rosa, BA
Kim Ross, MD, Danielle Garcia, BS, Larissa De La Rosa, BA
Space Dermatology: cutaneous changes from the final frontier
Alexa Kassels, BS, Jagmeet Arora, BS, Shay N. Sharma, Ajay N. Sharma, MD, MBA
Alexa Kassels, BS, Jagmeet Arora, BS, Shay N. Sharma, Ajay N. Sharma, MD, MBA
The Challenge of Clinical and Histologic Diagnosis of Porocarcinoma in a Patient with Multiple Nonmelanoma Skin Cancers
Tebyan Khalfalla, BS, Aamir Hussain, MD, MAPP, Amor Khachemoune, MD,
Tebyan Khalfalla, BS, Aamir Hussain, MD, MAPP, Amor Khachemoune, MD,
A Case of Immune Checkpoint Inhibitor-Induced Cicatricial Alopecia
Nelly Kokikian, BS , Carolyn Goh, MD
Nelly Kokikian, BS , Carolyn Goh, MD
Clinical Course of Pediatric Androgenetic Alopecia
Danny Lee BA, BS, Dawn Eichenfield, MD, PhD
Danny Lee BA, BS, Dawn Eichenfield, MD, PhD
Nevus Comedonicus Syndrome
Lourdes M. López, BS; Sarah Woodside, MD; Jared Roberts, MD
Lourdes M. López, BS; Sarah Woodside, MD; Jared Roberts, MD
Itch: from the skin to the brain – peripheral and central neural sensitization in chronic itch
Rami H. Mahmoud, BS, Omar Mahmoud, BS, Olusola Oladipo, PhD, Gil Yosipovitch, MD
Rami H. Mahmoud, BS, Omar Mahmoud, BS, Olusola Oladipo, PhD, Gil Yosipovitch, MD
Adult patients with alopecia areata report a significantly better medication adherence compared to those with atopic dermatitis – results from a large cross-sectional cohort study
Mischa Mallbris: Candidate, Lea Krog Nymand: Candidate, Yuki Maria Fukuda Andersen, MD, PhD, Alexander Egeberg, MD, PhD
Mischa Mallbris: Candidate, Lea Krog Nymand: Candidate, Yuki Maria Fukuda Andersen, MD, PhD, Alexander Egeberg, MD, PhD
Exploring Amyl Nitrate-Induced Dermatitis Through a Scoping Review
Stephanie Marín, BS, Roy Mendoza, BS, Joslyn Santana, BS, Howard Maibach, MD
Stephanie Marín, BS, Roy Mendoza, BS, Joslyn Santana, BS, Howard Maibach, MD
Association between psoriasis and chronic bronchitis among U.S. adults in the 2009-2014 National Health and Nutrition Examination Survey
Sara Osborne, BS, Olivia Kam, BA, Raquel Wescott, BS, Carolynne Vo, BS, Shivani Thacker, DO5, Jashin J. Wu, MD6
Sara Osborne, BS, Olivia Kam, BA, Raquel Wescott, BS, Carolynne Vo, BS, Shivani Thacker, DO5, Jashin J. Wu, MD6
Association between manual labor and sunburns among U.S. adults
Sara Osborne, BS, Olivia Kam, BA, Raquel Wescott, BS, Carolynne Vo, BS, Shivani Thacker, DO, Jashin J. Wu, MD6
Sara Osborne, BS, Olivia Kam, BA, Raquel Wescott, BS, Carolynne Vo, BS, Shivani Thacker, DO, Jashin J. Wu, MD6
Gender differences in sexual health impairment in chronic urticaria: A systematic review
Sarah E. Park, BA, Elaine Ma, BS, Terri Shih, MD, Vivian Y. Shi, MD, Jennifer L. Hsiao, MD
Sarah E. Park, BA, Elaine Ma, BS, Terri Shih, MD, Vivian Y. Shi, MD, Jennifer L. Hsiao, MD
Pachydermodactyly in an Adolescent Male
Bailey Patrick, BS, Benjamin Casterline, MD, PhD, Kari Martin, MD, Kara Braudis, MD
Bailey Patrick, BS, Benjamin Casterline, MD, PhD, Kari Martin, MD, Kara Braudis, MD
Exploring the Potential Role for Extended Reality in Mohs Micrographic Surgery
Anika Pulumati, BA, Yanci A. Algarin, BS, Dana Jaalouk, BS, Melanie Hirsch,BA, Keyvan Nouri, MD, MBA
Anika Pulumati, BA, Yanci A. Algarin, BS, Dana Jaalouk, BS, Melanie Hirsch,BA, Keyvan Nouri, MD, MBA
Use of Systemic Therapies for Vulvar Lichen Sclerosus and Vulvovaginal Lichen Planus: A Survey Study of Dermatologists and Gynecologists
Celeste Richardson, BS, Alexa Kassels, BS, Ashley Elsensohn MD MPH, Olushola L. Akinshemoyin Vaughn MD, Christina Kraus MD
Celeste Richardson, BS, Alexa Kassels, BS, Ashley Elsensohn MD MPH, Olushola L. Akinshemoyin Vaughn MD, Christina Kraus MD
Association of elevated transferrin saturation with lower prevalence of skin cancer diagnosis among adults: analysis of the third National Health and Nutritional Examination Survey (NHANES III)
Courtney A. Smith, MS, Tomas Ganz, MD, PhD, Elizabeta Nemeth, PhD, Lawrence Kuklinski, MD
Courtney A. Smith, MS, Tomas Ganz, MD, PhD, Elizabeta Nemeth, PhD, Lawrence Kuklinski, MD
Coma Blister Following Trazodone Misuse: A Case Report
Seanna Yang, BS, Vivien Chen MD, Carole Bitar MD
Seanna Yang, BS, Vivien Chen MD, Carole Bitar MD
